Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Dementia in People with Type 2 Diabetes-A Population-Based Cohort Study

被引：0
|
作者：
Tang, Huilin
Shaaban, C. Elizabeth
Wu, Yonghui
Magoc, Tanja
Donahoo, William T.
Dekosky, Steven T.
Bian, Jiang
Guo, Jingchuan
机构：
来源：
DIABETES | 2023年 / 72卷
关键词：
D O I：
10.2337/db23-894-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
894-P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes
    Paik, Julie M.
    Tesfaye, Helen
    Curhan, Gary C.
    Zakoul, Heidi
    Wexler, Deborah J.
    Patorno, Elisabetta
    JAMA INTERNAL MEDICINE, 2024, 184 (03) : 265 - 274
  • [22] Sodium-glucose cotransporter 2 inhibitors for the management of type 2 diabetes
    Siamashvili, Maka
    Davis, Stephen N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (16) : 2181 - 2198
  • [23] INITIATION OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS AND RECURRENT GOUT FLARES IN GOUT PATIENTS WITH TYPE 2 DIABETES: A GENERAL POPULATION-BASED COHORT STUDY
    Mccormick, N.
    Yokose, C.
    Wei, J.
    Lu, L.
    Wexler, D.
    Avina-Zubieta, J. A.
    De Vera, M.
    Zhang, Y.
    Choi, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 103 - 104
  • [24] Patterns and Patients' Characteristics Associated With Use of Sodium-Glucose Cotransporter-2 Inhibitors Among Adults With Type 2 Diabetes: A Population-based Cohort Study
    Campbell, Dennis B.
    Campbell, David J. T.
    Au, Flora
    Beall, Reed F.
    Ronksley, Paul E.
    Chew, Derek S.
    Ogundeji, Yewande
    Manns, Braden J.
    Hemmelgarn, Brenda R.
    Tonelli, Marcello
    Quinn, Amity E.
    CANADIAN JOURNAL OF DIABETES, 2023, 47 (01) : 58 - +
  • [25] Cumulative sodium-glucose cotransporter 2 inhibitor exposure and incident dementia: A population-based cohort analysis
    Wu, Che-Yuan
    Iskander, Carina
    Wang, Christa
    Xiong, Lisa Y.
    Shah, Baiju R.
    Edwards, Jodi D.
    Kapral, Moira K.
    Herrmann, Nathan
    Lanctot, Krista L.
    Cogo-Moreira, Hugo
    MacIntosh, Bradley J.
    Rabin, Jennifer S.
    Black, Sandra E.
    Saskin, Refik
    Swardfager, Walter
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 28 - 28
  • [26] Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia
    Hong, Bin
    Bea, Sungho
    Ko, Hwa Yeon
    Kim, Woo Jung
    Cho, Young Min
    Shin, Ju-Young
    ANNALS OF INTERNAL MEDICINE, 2024,
  • [27] Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of AKI in Older Adults with Type 2 Diabetes
    Zhuo, Min
    Paik, Julie M.
    Wexler, Deborah J.
    Bonventre, Joseph V.
    Kim, Seoyoung C.
    Patorno, Elisabetta
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 132 - 133
  • [28] Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes
    Abrahami, Devin
    Douros, Antonios
    Yin, Hui
    Yu, Oriana H. Y.
    Azoulay, Laurent
    DIABETES CARE, 2019, 42 (09) : E150 - E152
  • [29] Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study
    Kim, Young-Gun
    Jeon, Ja Young
    Han, Seung Jin
    Kim, Dae Jung
    Lee, Kwan-Woo
    Kim, Hae Jin
    DIABETES OBESITY & METABOLISM, 2018, 20 (08): : 1852 - 1858
  • [30] Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
    Vivian, Eva
    DIABETES EDUCATOR, 2015, 41 : 5S - 18S
12345